Acute myeloid leukaemias

European Journal of Cancer

Volumn 34, Issue 6, 1998, Pages 862-872

  Ritter, J ^a  

^a UNIVERSITY HOSPITAL MÜNSTER   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ACUTE GRANULOCYTIC LEUKEMIA; CANCER CLASSIFICATION; CANCER DIAGNOSIS; DIFFERENTIAL DIAGNOSIS; HUMAN; LEUKEMOGENESIS; PRIORITY JOURNAL; REVIEW;

EID: 0032077396     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0959-8049(98)00132-4     Document Type: Article

References (116)

1. Cline MJ. The molecular basis of leukemia. N Engl J Med 1994, 330, 328-336.
2. Creutzig U. Diagnosis and treatment of acute myelogenous leukemia in childhood. Crit Rev Oncol Hematol 1996, 22, 183-196.
3. Lie SO. Acute myelogenous leukaemia in children. Eur J Pediatr 1991, 148, 382-388.
4. Ritter J, Creutzig U, Reiter A, Riehm H, Schellong G. Childhood leukemia: cooperative Berlin-Frankfurt-Munster trials in the Federal Republic of Germany. J Cancer Res Clin Oncol 1990, 116, 100-103.
5. Vormoor J, Boos J, Stahnke K, Jürgens H, Ritter J, Creutzig U. Therapy of childhood acute myelogenous leukemia. Ann Hematol 1996, 73, 11-24.
6. Hurwitz CA, Mounce KG, Grier HE. Treatment of patients with acute myelogenous leukemia: review of clinical trials of the past decade. J Pediatr Hematol Oncol 1995, 17, 185-197.
7. Pui CH. Childhood leukemias. N Engl J Med 1995, 332, 1618-1630.
8. Lie SO. Treatment of acute myeloid leukaemia in children. Bailliere's Clinical Paediatrics 1995, 3, 757-778.
9. Creutzig U, Ritter J, Zimmermann M, Boos J, Bender-Götze C, Stahnke K. Risk factors for survival in children with refractory AML treated according to AML relapse strategies. Haematol Blood Transf 1997, VII, 810-817.
10. Tucker MA, Meadows AT, Boice JD Jr, et al. Leukemia after therapy with alkylating agents for childhood cancer. J Natl Cancer Inst 1987, 78, 459-464.
11. Blayney DW, Longo DL, Young RC, et al. Decreasing risk of leukemia with prolonged follow-up after chemotherapy and radiotherapy for Hodgkin's disease. N Engl J Med 1987, 316, 710-714.
12. Rubin C, Arthur D, Woods W. Therapy related MDS and AML in children: correlation between chromosomal abnormalities and prior therapy. Blood 1991, 78, 2982-2988.
13. Rowley JD, Golomb HM, Vardiman JW. Non-random chromosome abnormalities in acute leukemia. Blood 1981, 58, 759-767.
14. Pui CH, Ribeirio R, Hancock ML. AML in children treated with epiphyllotoxins for ALL. N Engl J Med 1991, 325, 1682-1688.
15. Thirman MJ, Gill HJ, Burnett RC, et al. Rearrangement of the MLL gene in acute lymphoblastic and acute myeloid leukemias with 11q23 chromosomal translocations [see comments]. N Engl J Med 1993, 329, 909-914.
16. Lazarus KH, Heerema NA, Palmer CC, Baehner RL. The myeloproliferative reaction in a child with Down's syndrome: cytological and chromosomal evidence for a transient leukemia. Am J Hematol 1981, 11,417-423.
17. Ravindranath Y, Steuber CP, Krischer J, et al. High-dose cytarabine for intensification of early therapy of childhood acute myeloid leukemia: a Pediatric Oncology Group study. J Clin Oncol 1991, 9, 572-580.
18. Wong KY, Jones MM, Srivastava AK, Gruppo RA. Transient myeloproliferative disorder and acute non lymphoblastic leukemia in Down's syndrome. J Pediatr 1988, 112, 18-22.
19. Creutzig U, Ritter J, Budde M, Sutor A, Schellong G. Early deaths due to hemorrhage and leukostasis in childhood acute myelogenous leukemia: associations with hyperleukocytosis and acute monocytic leukemia. Cancer 1987, 60, 3071-3079.
20. Bennett JM, Catovsky D, Daniel MT, et al. Proposals for the classification of the acute leukaemias. Br J Haematol 1976, 33, 451-458.
21. Bennett JM, Catovsky D, Daniel MT, et al. Proposed revised criteria for the classification of acute myeloid leukemia. Ann Intern Med 1985, 103, 626-629.
22. Bennett JM, Catovsky D, Daniel MT, et al. Criteria for the diagnosis of acute leukemia of megakaryocyte lineage (M7). A report of the French-American-British Cooperative Group. Ann Intern Med 1985, 103, 460-462.
23. Bennett JM, Catovsky D, Daniel MT, et al. Proposal for the recognition of minimally differentiated acute myeloid leukaemia (AML-MO). BrJ Haematol 1991, 78, 325-329.
24. Bennett JM, Catovsky D, Daniel MT, et al. Proposals for the classification of the myelodysplastic syndromes. Br J Haematol 1982, 51, 189-199.
25. Creutzig U, Cantú Rajnoldi A, Ritter J, et al. Myelodysplastic syndromes in childhood: report of 21 patients from Italy and West-Germany. A m J Pediatr Hematol Oncol 1987, 9, 324-330.
26. Creutzig U, Ritter J, Vormoor J, et al. Myelodysplasia and acute myelogenous leukemia in Down's syndrome. A report of 56 children of the AML-BFM Study Group. Leukemia 1996, 10, 1677-1686.
27. Ritter J, Creutzig U, Suttorp M, et al. Acute megakaryoblastic leukemia (FAB M7) in children: analysis of 13 patients in the german cooperative AML-BFM-87 study. Ann Hematol 1992, 64, 85 (Abstract).
28. Schlossman SF, Boumsell L, Gilks W, et al. CD antigens 1993. Immunol Today 1994, 15, 98-99.
29. Ludwig WD, Herrmann F, Gatzke A, et al. Surface marker analysis by monoclonal antibodies: a valuable technique in childhood acute myeloid leukemia. Haematol Blood Transf 1987, 30, 418-422.
30. Ludwig WD, Harbott J, Bartram CR, et al. Incidence and prognostic significance of immunophenotypic subgroups in childhood acute lymphoblastic leukemia: experience of the BFM study 86. Recent Results Cancer Res 1993, 131, 269-282.
31. Pui CH, Behm FG, Singh B, et al. Myeloid-associated antigen expression lacks prognostic value in childhood acute lymphoblastic leukemia treated with intensive multiagent chemotherapy. Blood 1990, 75, 198-202.
32. Creutzig U, Sperling C, Harbott J, et al. Clinical significance of surface antigen expression in children with acute myeloid leukemia: results of Study AML-BFM-87. Blood 1995, 86, 3097-3108.
33. Catovsky D, Matutes E, Buccheri V, et al. A classification of acute leukaemia for the 1990s. Blut 1991, 62, 16-21.
34. Second MIC Cooperative Study Group. Morphologic, immunologic, and cytogenetic (MIC) working classification of the acute myeloid leukaemias. Br J Haematol 1988, 68, 487-494.
35. Goldberg MA, Ginsburg D, Mayer RJ, et al. Is heparin administration necessary during induction chemotherapy for patients with acute promyelocytic leukemia? Blood 1987, 69, 187-191.
36. Castaigne S, Chomienne C, Daniel MT, et al. All-trans retinoic acid as a differentiation therapy for acute promyelocytic leukemia. I. Clinical results. Blood 1990, 76, 1704-1709.
37. Pizzo PA. Considerations for the prevention of infectious complications in patients with cancer. Rev Infect Dis 1989, 11 (Suppl. 7), S1551-S1563.
38. Cuttner J, Holland JF, Norton L, Ambinder E, Button G, Meyer RJ. Therapeutic leukapheresis for hyperleukocytosis in acute myelocytic leukemia. Med Pediatr Oncol 1983, 11, 76-78.
39. Grund FM, Armitage JO, Burns P. Hydroxyurea in the prevention of the effects of leukostasis in acute leukemia. Arch Intern Med 1977, 137, 1246-1247.
40. Hiddemann W. Cytosine arabinoside in the treatment of acute myeloid leukemia: the role and place of high-dose regimens. Ann Hematol 1991, 62, 119-128.
41. Rustum YM, Raymakers RA. 1 -Beta-arabinofuranosylcytosine in therapy of leukemia: preclinical and clinical overview. Pharmacol Ther 1992, 56, 307-321.
42. Rai KR, Holland JF, Glidewell OJ, et al. Treatment of acute myelocytic leukemia: a study by Cancer and Leukemia Group B. Blood 1981, 58, 1203-1212.
43. Yeager AM, Kaizer H, Santos GW, et al. Autologous bone marrow transplantation in patients with acute nonlymphocytic leukemia, using ex vivo treatment with 4-hydroperoxycyclophosphamide. N Engl J Med 1986, 315, 141-147.
44. Creutzig U, Ritter J, Schellong G. Identification of two risk groups in childhood acute myelogenous leukemia after therapy intensification in the study AML-BFM-83 as compared with study AML-BFM-78. Blood 1990, 75, 1932-1940.
45. Creutzig U, Ritter J, Zimmermann M, Schellong G, for the AML-BFM Study Group. Does cranial irradiation reduce the risk for bone marrow relapse in acute myelogenous leukemia (AML): unexpected results of the childhood AML Study BFM-87. J Clin Oncol 1993, 1, 279-286.
46. Nesbit ME, Buckley JD, Feig SA, et al. Chemotherapy for induction of remission of childhood acute myeloid leukemia followed by marrow transplantation or multiagent chemotherapy - a report from the Children's Cancer Group. J Clin Oncol 1994, 12, 127-135.
47. Schellong G, Creutzig U, Ritter J. Treatment of acute myelogenous leukemia in children. Med Oncol Tumor Pharmacother 1985, 2, 17-25.
48. Ravindranath Y, Chang M, Gresik M, et al. Intensive consolidation chemotherapy (IGT) vs autologous bone marrow transplantation (ABMT) in first remission of childhood AML: experience on pediatric oncology group study-POG 8821. Med Pediatr Oncol 1995, 25, 271.
49. Wells RJ, Woods WG, Buckley JD, et al Treatment of newly diagnosed children and adolescents with acute myeloid leukemia: a Childrens Cancer Group Study. J Clin Oncol 1994, 12, 2367-2377.
50. Woods WG, Kobrinsky N, Buckley JD, et al. Timed-sequential induction therapy improves postremission outcome in acute myeloid leukemia: a report from the Children's Cancer Group. Blood 1996, 87, 4979-4989.
51. Hann IM, Stevens RF, Goldstone AH, et al. Randomized comparison of DAT versus ADE as induction chemotherapy in children and younger adults with acute myeloid leukemia. Results of the Medical Research Council's 10th AML trial (MRC AML 10). Adult and Childhood Leukaemia Working Parties of the Medical Research Council. Blood 1997, 89, 2311-2318.
52. Bishop JF, Matthews JP, Young GA, et al. A randomized study of high-dose cytarabine in induction in acute myeloid leukemia [see comments]. Blood 1996, 87, 1710-1717.
53. Büchner T, Hiddemann W, Wörmann B, Schellong G, Ritter J, eds. Chemotherapy intensity and long-term outcome in AML. Acute Leukemias IV. Heidelberg, Berlin, Springer-Verlag, 1994, 513-518.
54. Grier HE, Gelber RD, Clavell LA, et al. Intensive sequential chemotherapy for children with acute myelogenous leukemia. Haematol Blood Transf 1990, 33, 193-197.
55. Packer RJ, Siegel KR, Sutton LN, et al. Efficacy of adjuvant chemotherapy for patients with poor-risk medulloblastoma: a preliminary report. Ann Neurol 1988, 24, 503-508.
56. Steuber CP, Civin C, Krischer J, et al. A comparison of induction and maintenance therapy for acute nonlymphocytic leukemia in childhood: results of a Pediatric Oncology Group Study. J Clin Oncol 1991, 9, 247-258.
57. Buckley JD, Chard RL, Baehner RL, et al. Improvement in outcome for children with acute nonlymphocytic leukemia. A report form the Children's Cancer Study Group. Cancer 1989, 63, 1457-1465.
58. Yates JG, Glidewell O, Wiernik P, et al. Cytosine arabinoside with daunorubicin or adriamycin for therapy of acute myelocytic leukemia: a CALGB study. Blood 1982, 60, 454-462.
59. Stevens RF, Hann IM. Marked improvement in outcome with chemotherapy alone in paediatric acute myeloid leukaemia: results of the United Kingdom Medical Research Council's 10th AML trial. Br J Haematol 1998 (in press).
60. Lipshultz SE, Colan SD, Gelber RD, Perez-Atayde AR, Sallan S, Sanders SP. Late cardiac effects of doxorubicin therapy for acute lymphoblastic leukemia in childhood. N Engl J Med 1991, 324, 808-815.
61. Bielack SS, Erttmann R, Kempf Bielack B, Winkler K. Impact of scheduling on toxicity and clinical efficacy of doxorubicin: what do we know in the mid-nineties? EurJ Cancer 1996, 32A, 1652-1660.
62. Berman E, Heller G, Santorsa J, et al. Results of a randomized trial comparing idarubicin and cytosine arabinoside with daunorubicin and cytosine arabinoside in adult patients with newly diagnosed acute myelogenous leukemia. Blood 1991, 77, 1666-1674.
63. Wiernik PH, Banks PLC, Case DC Jr, et al. Cytarabine plus idarubicin or daunorubicin as induction and consolidation therapy for previously untreated adult patients with acute myeloid leukemia. Blood 1992, 79, 313-319 (Abstract).
64. Vogler WR, Velez-Garcia E, Weiner RS, et al. A phase III trial comparing idarubicin and daunorubicin in combination with cytarabine in acute myelogenous leukemia: a Southeastern Cancer Study Group. J Clin Oncol 1992, 10, 103-111 (Abstract).
65. Ritter J, Creutzig U, Zimmermann M. The specific role of idarubicin during induction therapy of childhood AML. Haematol Blood Transf 1996, 38, 396-399.
66. Sackmann Muriel F, Zubizarreta P, Felice MS, et al. Results of treatment with an intensive induction regimen using idarubicin in combination with cytarabine and etoposide in children with acute myeloblastic leukemia. Leuk Res 1996, 20, 973-981.
67. Creutzig U, Schrappe M. Akute Leukämien im Kindesalter. Internist 1996, 37, 982-993.
68. Gill PS, Wernz J, Scadden DT, et al. Randomized phase III trial of liposomal daunorubicin versus doxorubicin, bleomycin, and vincristine in AIDS-related Kaposi's sarcoma. J Clin Oncol 1996, 14, 2353-2364.
69. Ravindranath Y, Steuber CP, Krischer J, et al. High-dose cytarabine for intensification of early therapy of childhood acute myeloid leukemia: a Pediatric Oncology Group study. J Clin Oncol 1991, 9, 572-580.
70. Weinstein H, Mayer R, Rosenthal D, et al. Chemotherapy for acute myelogenous leukemia in children and adults. VAPA update. Blood 1983, 62, 315-319.
71. McLeod HL, Relling MV, Crom WR, et al. Disposition of antineoplastic agents in the very young child. BrJ Cancer 1992, 18 (Suppl.), S23-S29.
72. Boos J, Krümpelmann S, Schulze Westhoff P, Euting T, Berthold F, Jürgens H. Steady-state levels and bone marrow toxicity of etoposide in children and infants: does etoposide require age-dependent dose calculation? J Clin Oncol 1995, 13, 2954-2960.
73. Periclou AP, Avramis VI. NONMEN population pharmacokinetic studies of cytosine arabinoside after high-dose and after loading bolus followed by continuous infusion of the drug in pediatric patients with leukemias. Cancer Chemother Pharmacol 1996, 39, 42-50.
74. Ramilo-Torno LV, Avramis VI. Continuous infusion cytosine arabinoside compound by high dose and conventional dose therapy in pediatric patients with relapsed leukemias. J Infus Chemo 1994, 4, 9-17.
75. Ritter J, Roos N. Special aspects related to invasive fungal infections in children with cancer. Bailliere's Clin Inf Dis 1995, 2, 179-204.
76. Büchner T, Urbanitz D, Hiddemann W, et al. Intensified induction and consolidation with or without maintenance chemotherapy for acute myeloid leukemia (AML) : two multicenter studies of the German AML Cooperative Group. J Clin Oncol 1985, 3, 1583-1589.
77. Grier HE, Gelber RD, Camitta BM, et al. Prognostic factors in childhood acute myelogenous leukemia. J Clin Oncol 1987, 5, 1026-1032.
78. Woods WG, Ruymann FB, Lampkin BC, et al. The role of timing of high-dose cytosine arabinoside intensification and of maintenance therapy in the treatment of children with acute non-lymphocytic leukemia. Cancer 1990, 66, 1106-1113.
79. Ritter J, Creutzig U, Schellong G. Improved treatment results in the myelocytic subtypes FAB M1-M4 but not in FAB M5 after intensification of induction therapy: results of the German childhood AML studies BFM-78 and -83. Haematol Blood Transf 1990, 33, 185-193.
80. Cassileth PA, Lynch E, Hines JD, et al. Varying intensity of postremission therapy in acute leukemia. Blood 1992, 79, 1924-1930.
81. Wolff S, Herzig R, Fay J, et al. High dose cytosine arabinoside and daunomycin as consolidation therapy for acute non-myeloid leukemia in first remission: long term results. J Clin Oncol 1989, 7, 1260-1267.
82. Mayer RJ, Davis RB, Schifffer CA, et al. Intensive postremission chemotherapy in adults with acute myeloid leukemia. N Engl J Med 1994, 331, 896-903.
83. Ritter J, Vormoor J, Creutzig U, Schellong G. Prognostic significance of Auer rods in childhood acute myelogenous leukemia: results of the studies AML-BFM-78 and -83. Med Pediatr Oncol 1989, 17, 202-209.
84. Ritter J, Creutzig U, Henze G, et al. [High dosage ARA-C in combination with mitoxantrone in therapy of acute myeloid leukemia in childhood. Initial results of the AML BFM-85 recurrence study]. Onkologie 1987, 10, 24-27.
85. Hiddemann W, Kreutzmann H, Straif K, et al. High-dose cytosine arabinoside and mitoxantrone: a highly effective regimen in refractory acute myeloid leukemia. Blood 1987, 69, 744-749.
86. Cassileth PA, Harrington DP, Hines JD, et al. Maintenance chemotherapy prolongs remission duration in adult acute non-lymphocytic leukemia. J Clin Oncol 1988, 6, 583-587.
87. Wells RJ, Woods WG, Lampkin BC, et al. Impact of high-dose cytarabine and asparaginase intensification on childhood acute myeloid leukemia: a report from the Childrens Cancer Group. 3 Clin Oncol 1993, 11, 538-545.
88. Dahl GV, Simone JV, Hustu HO, Mason C. Preventive central nervous system irradiation in children with acute non-lymphocytic leukemia. Cancer 1978, 42, 2187-2192.
89. Grier HE, Gelber RD, Link MP, Camitta BP, Clavell LA, Weistein HJ. Intensive sequential chemotherapy for children with acute myelogenous leukemia: VAPA, 80-035, and HI-C-Daze. Leukemia 1992, 6 (Suppl. 2), 19-22.
90. Witherspoon RP, Fisher LD, Schoch G, et al. Secondary cancers after bone marrow transplantation for leukemia or aplastic anemia [see comments]. N Engl J Med 1989, 321, 784-789.
91. Wingard JR, Plotnick LP, Freemer CS, et al. Growth in children after bone marrow transplantation: busulfan plus cyclophosphamide versus cyclophosphamide plus total body irradiation. Blood 1992, 79, 1068-1073.
92. Appelbaum FR, Fisher LD, Thomas ED. Chemotherapy versus marrow transplantation for adults with acute non-lymphocytic leukemia: a five-year follow-up. Blood 1988, 72, 179-184.
93. Liesner RJ, Leiper AD, Hann IM, Chessells JM. Late effects of intensive treatment for acute myeloid leukemia and myelodysplasia in childhood. J Clin Oncol 1994, 12, 916-924.
94. Amadori S, Testi AM, Aricó M, et al. Prospective comparative study of bone marrow transplantation and postremission chemotherapy for childhood acute myelogenous leukemia. J Clin Oncol 1993, 11, 1046-1054.
95. Feig SA, Lampkin B, Nesbit ME, et al. Outcome of BMT during first complete remission of AML: a comparison of two sequential studies by the Childrens Cancer Group. Bone Marrow Transplantation 1993, 12, 65-71.
96. Lange B, Woods W, Lampkin B, et al. Childrens Cancer Group transplant trials for acute myeloid leukemia in children: a cross-study analysis of CCG-251, CCG-213, CCG-2861, and CCG-2891. In Büchner T, Hiddemann W, Wörmann B, Ritter J, Schellong G, eds. Acute Leukemias IV. 4th edn Berlin, Heidelberg; New York, Springer, 1993, 724-733.
97. Creutzig U, Bender-Götze C, Klingebiel T, et al. Vergleich der alleinigen Chemotherapie mit der allogenen Knochenmark-transplantation in erster Vollremission bei Kindern mit akuter myeloischer Leukamie in den Studien AML-BFM-83 und AML-BFM-87-Matched Pair Analyse. Klin Pädiatr 1992, 204, 246-252.
98. Creutzig U, Ritter J, Zimmermann M, Bender-Götze C, Schellong G. Bone-marrow transplantation [letter]. Lancet 1995, 346, 60.
99. Creutzig U, Ritter J, Zimmermann M, Bender-Götze C, Schellong G. Seven-year survival exceeding 70% without bone-marrow transplantation in first remission in standard risk children with acute myelogenous leukemia: results of studies AML-BFM-83 and -87. Blood 1995, 86, 433a (Abstract).
100. Gorin NC, Aegerter P, Auvert B, et al. Autologous bone marrow transplantation for acute myelogenous leukemia in first remission: a European survey of the role of marrow purging. Blood 1990, 75, 1606-1614.
101. Cassileth PA, Andersen J, Lazarus HM, et al. Autologous bone marrow transplant in acute myeloid leukemia in first remission. J Clin Oncol 1993, 11, 314-319.
102. Brenner MK, Rill DR, Moen RC, et al Gene marking and autologous bone marrow transplantation. Ann N Y Acad Sci 1994, 716, 716-721.
103. Laporte JP, Douay L, Lopez M, et al. One hundred twenty-five adult patients with primary acute leukemia autografted with marrow purged by mafosfamide: a 10-year single institution experience. Blood 1994, 84, 3810-3818.
104. Yeager AM, Rowley SD, Kaizer H, Santos GW. Ex vivo chemopurging of autologous bone marrow with 4-hydroperoxycyclophosphamide to eliminate occult leukemic cells. Laboratory and clinical observations. Am J Pediatr Hematol Oncol 1990, 12, 245-256.
105. Ravindranath Y, Yeager AM, Chang MN, et al. Autologous bone marrow transplantation versus intensive consolidation chemotherapy for acute myeloid leukemia in childhood. Pediatric Oncology Group. N Engl J Med 1996, 334, 1428-1434.
106. Feeny D, Leiper A, Bar RD, et al. The comprehensive assessment of health status in survivors of childhood cancer: application to high-risk acute lymphoblastic leukaemia. Br J Cancer 1993, 67, 1047-1052.
107. Barr RD, Furlong W, Dawson S, et al. An assessment of global health status in survivors of acute lymphoblastic leukemia in childhood. Am J Ped Hemat and Oncol 1993,15, 284-290.
108. Degos L, Dombret H, Chomienne C, et al. All-zraws-retinoic acid as a differentiating agent in the treatment of acute promyelocytic leukemia. Blood 1995, 85, 2643-2653.
109. Campana D, Coustan-Smith E, Janossy G. The immunologic detection of minimal residual disease in acute leukemia. Blood 1990, 76, 163.
110. Wörmann B, Feuring-Buske M, Haase D, et al. Immunophenotypical detection of MRD in AML. International Symposium MRD 1998, in press.
111. Boos J, Holhenlöchter B, Schulze-Westhoff P, et al. Intracellular retention of cytosine-arabinoside-triphosphate in blast cells from children with acute myelogenous and lymphoblastic leukemia. Med Pediatr Oncol 1996, 26, 397-404.
112. Santana VM, Hurwitz CA, Blakley RL, et al. Complete hematologic remissions induced by 2-chlorodeoxyadenosine in children with newly diagnosed acute myeloid leukemia. Blood 1994, 84, 1237-1242.
113. Gandhi V, Estey E, Keating MJ, Plunkett W. Fludarabine potentiates metabolism of cytarabine in patients with acute myelogenous leukemia during therapy. J Clin Oncol 1993, 11, 116-124.
114. Kaspers GJL, Rottier MMA, Creutzig U, Ritter J, Pieters R, Veerman AJP. Cellular drug resistance in childhood AML. Ann Hematol 1997, 74 (Abstract).
115. Klumper E, Pieters R, Kaspers GJL, et al. In vitro chemosensitivity assessed with the MTT assay in childhood acute non-lymphoblastic leukemia. Leukemia 1995, 9, 1864-1869.
116. Vose JM, Armitage JO. Clinical applications of hematopoietic growth factors [see comments]. J Clin Oncol 1995, 13, 1023-1035.